Author of

• 16549

  +

  P1.02 - Poster Session with Presenters Present (ID 454)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16550

    +

    P1.02-001 - Expressions of Resistance EGFR TKIs in Non Small Cell Lung CancerAt Pham Ngoc Thach Hospital - Viet Nam (ID 3747)

    14:30 - 14:30  |  Author(s): N.N. Vu
    • Abstract
    • Slides

    Background:
    In the patients with NSCLC were tested for diagnostic EGFR mutation, in addition to activating mutations, such as Exon 19 Deletion & Exon 21 L858R that is occupies a large amount. The mutation is said to be resistant to EGFR TKIs occupies smaller amount. However, this is also a challenge for the care and treatment for patients with NSCLC.
    
    Methods:
    Retrospective, cross-sectional descriptive statistics, clinical case series.
    
    Results:
    PRIMARY MUTATIONS WITH EGFR TKIs RESISTANCE §Activating EGFR Mutations: Exon 19 Deletion: 356/597 cases = 59,63% and Exon 21 L858R: 176/597 cases = 29,48%. §Primary Mutations with EGFR TKIs Resistance - Single mutations: 46/597 cases = 7,71% (Male: 27 cases + Female: 19 cases), including: Exon 20 Insertion: 25 cases, Exon 18 G719X: 14 cases, Exon 20 S768i: 5 cases, Exon 20 T790M: 2 cases. §Primary Mutations with EGFR TKIs Resistance - Double mutations: 19 / 597 cases = 3,18% (Male: 11 cases + Female: 8 cases), including: Exon 21 L858R + Exon 20 T790M: 6 cases, Exon 19 Deletion + Exon 20 T790M: 5 cases, Exon 18 G719X + Exon 20 Insertion: 2 cases, Exon 21 L858R + Exon 20 G786i: 3 cases, Exon 18 G719X + Exon 20 S768i: 3 cases. ACQUIRED MUTATIONS WITH EGFR TKIs RESISTANCE §Total cases with the gene mutation diagnosis repeating again (Sampling with Histology or Cytology): 113/597 cases (18,93%). Detection rate for new resistance EGFR TKIs mutations: Number of Cases: 56 cases/113 cases (49,56%). §Distribution rate % of acquired resistance mutations in EGFR TKIs: · Exon 20 T790M (Single & Double Mutations): 28 cases (50 %) · MET Amplification: 4 cases (7,14 %) · HER2 Amplification: 13 cases (23,21 %) · Small Cell Carcinoma Transformation: 5 cases (8,93 %) · PIK3CA Mutation: 2 cases (3,58 %) · The Other Mutations: 4 cases (7,14 %) §The expression of EGFR T790M mutation: T790M Single Mutation: 14 cases; T790M + Exon 20 Insertion: 3 cases; T790M + A763V: 4 cases; T790M + L777G: 1 case; T790M + Y801C: 3 cases; T790M + G719X: 2 cases; T790M + S768i: 1 case.
    
    Conclusion:
    § There are the expressed resistance mutations EGFR TKIs in NSCLC patients at Pham Ngoc Thach Hospital, including: Primary EGFR TKIs Resistance & Acquired EGFR TKIs Resistance. § The rate of drug-resistant mutant EGFR TKIs are small but still important issues in the Care and Treatment of lung cancer.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.